Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)

Added 32 days ago (27.10.2021)
Authors: Sanjay Popat; Geoffrey Liu; Shun Lu; Gregory Song; Xin Ma; James Chih-Hsin Yang
Read article